St. Jude Medical authorizes $700M share repurchase; Medtronic starts trial for vitamin-sized pacemaker;

@FierceMedDev: Edwards looks to a rocky 2014 as Medtronic looms. More | Follow @FierceMedDev

@MarkHFierce: $100M gets CareFusion a minority stake in an Israeli infusion pump maker--they're old friends as well. Story | Follow @MarkHFierce

@MichaelGFierce: New Hologic CEO aims for Dx revenue growth over sale option. Item | Follow @MichaelGFierce

@GalenMoore: Genetic testing: Invitae completes a $40 million series E financing. Release | Follow @GalenMoore

> St. Jude Medical's ($STJ) board of directors authorized a share repurchase of up to $700 million shares of common stock. Item

> Medtronic ($MDT) has launched a global clinical trial of a transcatheter pacemaker system the size of a large vitamin, and the first patient recently received the implant in Austria. Item

> NeuroMetrix ($NURO) said it will work with Omron Medical Devices to distribute its test for diabetic peripheral neuropathy in China. Item

> An FDA advisory panel will consider on Dec. 11 whether to recommend approval for Boston Scientific's ($BSX) Watchman implant, designed to prevent strokes. Story

> Endo Health Solutions' ($ENDP) American Medical Systems arm won the FDA's 510(k) clearance for a new sling system to treat female stress urinary incontinence. Item

> Researchers have developed a mathematical model designed to improve how stents are used to treat coronary heart disease. Item

Biotech News

@FierceBiotech: Alzheimers R&D: The biggest lottery in the industry, with a winning ticket worth an overnight fortune. Story | Follow @FierceBiotech

@JohnCFierce: So what are the 5 worst pharma media ops? Novartis certainly makes the list. Merck of course. Other suggestions? | Follow @JohnCFierce

@DamianFierce: The FDA's still wary of dapagliflozin, AstraZeneca and Bristol-Myers Squibb's once-rejected diabetes drug. More | Follow @DamianFierce

@EmilyMFierce: Nobel winner declares boycott of top science journals. Story via The Guardian | Follow @EmilyMFierce

> AbbVie's second PhIII hep C study confirms cocktail's promise. Item

> Danish officials cite Novo Nordisk for delay of game. Article

> Takeda sways FDA panel with its bowel disease drug despite viral risks. More

> FDA raises safety, efficacy questions for Bristol-Myers' rare-disease drug metreleptin. News

Pharma News

@FiercePharma: Teva braces for a $550M hit from Copaxone generics. Story | Follow @FiercePharma

@EricPFierce: As this story says, Merck was getting heat on Fosamax litigation it is now settling. News | Follow @EricPFierce

@CarlyHFierce: Pfizer loses Supreme Court bid to squash $142M Neurontin verdict. More | Follow @CarlyHFierce

> Drugmakers, beware of tweets that trigger stock moves. Story

> Novo Nordisk in hot water for delaying bad news on Tresiba. News

Pharma Manufacturing News

> Track-and-trace is here ... and now. Editor's corner

> FDA spanks a second Jubilant HollisterStier plant. More

> Alvogen makes a $250M biosimilars investment in Iceland. Story

> Biogen API plant gets nicked by the FDA. Article

> Hospira cuts costs by expanding drug and API production outside of the U.S. News

> Pharma Tech adds capacity as the CMO industry heats up. Report

> Feds close down importer that sold unapproved Botox and cancer drugs. Item

Biotech Research News

> Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. More

> GlaxoSmithKline initiates global cancer consortium. Item

> Report: Global malaria R&D needs $8.3B boost over next decade. Story

> Gene discovery could predict responsiveness of antidepressants. Report

> International Stem Cell Corp. finds a new way to reprogram cells. News

> 1 in 100 cancers associated with gene mutation. Article

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.